Donepezil, rivastigmine, galantamine and memantine for ...

CIBIC-plus scale showed the benefits of treatment
with galantamine compared with placebo for
different doses and lengths of study, although
these were not statistically significant (see
Figures 16–18). The fixed-effect model for
24–32 mg/day galantamine compared with
Review:
Comparison:
Outcome:
Study
or sub-category
Raskind 2000 gal
Wilcock 2000 gal
Alzheimer 2003
08 Galantamine CIBIC responders
02 Galantamine 24 at 5–6 months
Treatment
n/N
Control
n/N
37/186 27/196
36/206 33/203
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Health Technology Assessment 2006; Vol. 10: No. 1
placebo showed an OR favouring galantamine at
3 months [OR 1.43 (95% CI: 0.98 to 2.08)] and for
galantamine 24 mg/day compared to placebo at
6 months follow-up [OR 1.29 (95% CI: 0.89 to
1.88)]. Similarly, the OR from the fixed-effect
models for 32 mg/day galantamine compared with
OR (fixed)
95% CI
Weight
%
43.43
56.57
OR (fixed)
95% CI
1.55 (0.90 to 2.67)
1.09 (0.65 to 1.83)
Total (95% CI)
Total events: 73 (Treatment), 60 (Control)
Test for heterogeneity: 2 = 0.86, df = 1 (p = 0.36), I2 392 399 100.00 1.29 (0.89 to 1.88)
= 0%
Test for overall effect: z = 1.34 (p = 0.18)
FIGURE 16 CIBIC-plus responders with galantamine 24 mg
Comparison:
Outcome:
Study
Rockwood 2001 gal
Wilkinson 2000 gal
08 Galantamine CIBIC responders
01 Galantamine 24–32 at 3 months
Treatment
n/N
Control
n/N
64/248 24/124
61/240 24/123
0.1 0.2 0.5 1 2 5 10
Favours control Favours treatment
OR
(95% CI fixed)
Weight
%
50.1
49.9
OR
(95% CI fixed)
1.45 (0.85 to 2.46)
1.41 (0.83 to 2.39)
Total (95% CI)
Test for heterogeneity 2 125/488 48/247 100.00 1.43 (0.98 to 2.08)
= 0.01, df = 1, p = 0.94
Test for overall effect: z = 1.86, p = 0.06
FIGURE 17 CIBIC-plus responders with galantamine 24–32 mg
Comparison:
Outcome:
Study
Raskind 2000 gal
Wilcock 2000 gal
08 Galantamine CIBIC responders
03 Galantamine 32 at 6 months
Treatment
n/N
Control
n/N
27/171 27/196
48/198 33/203
0.1 0.2 1 5 10
Favours control Favours treatment
OR
(95% CI fixed)
Weight
%
46.2
53.8
OR
(95% CI fixed)
1.17 (0.66 to 2.09)
1.65 (1.01 to 2.70)
Total (95% CI)
Test for heterogeneity 2 75/369 60/399 100.00 1.43 (0.98 to 2.08)
= 0.77, df = 1, p = 0.38
Test for overall effect: z = 1.87, p = 0.06
FIGURE 18 CIBIC-plus responders with galantamine 32 mg
0.1 0.2 1 5 10
Favours control Favours treatment
61